AX-158

AX-158 is a first-in-class, oral small molecule immunomodulating agent developed by Artax Biopharma for the treatment of T cell-mediated diseases, particularly autoimmune disorders such as plaque psoriasis. Its novel mechanism of action involves selective inhibition of the Nck SH3.1 domain, a protein that amplifies T cell signaling at the T cell receptor (TCR), thereby modulating disease-related genes and immune responses without causing immunosuppression. Clinical trials have demonstrated that AX-158 can impact relevant biomarkers and improve clinical outcomes in patients with mild to moderate plaque psoriasis, with a favorable safety profile and no severe adverse effects reported[1][2][3][5][8]. Preclinical data suggest broad potential for treating various autoimmune diseases by modulating Th1, Th2, and Th17 pathways while preserving normal immune defense against pathogens[6][8].